India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
Mobile Phones are a very important part of our daily life. From calling and messaging…
Mongolian parliament has appointed the Uchral Nyam-Osor as the country' new Prime Minister. With this…
To boost export potential of Indian textile industries Ministry of Textiles has extended the RoSCTL…
From the April 1st fuel stations across the country are now supplying that petrol which…
The Ministry of Education has granted the 'deemed to be university’ status to National Council…
India's Gaganyaan Mission have begun the unique experiment which is called Mission Mitra in the…